传电子烟初创Juul拟裁员逾半 仅保留千人
外电昨日(4日)报道指,万宝路生产商奥驰亚(Altria Group)(MO.US)为最大投资者的电子烟初创Juul Labs Inc.指正计划新一轮大规模裁员,并考虑结束欧洲及亚洲多国销售。据《华尔街日报》进一步引消息称,Juul计划裁员超过一半,团队将由目前的约2,200人降至约1,000人。
Juul发言人称,公司未有最终决定,并持续进行评估。
今年较早时间Juul已裁减其3,000人团队的约三分之一,并已结束数个国家的雾化器销售。进一步退出欧亚多国市场,意味公司退出多达11个国家,仅维持在美国、加拿大及英国的核心市场。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.